Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy

被引:42
作者
Nakagawa, T
Yokozawa, T
Terasawa, K
Nakanishi, K
机构
[1] Toyama Med & Pharmaceut Univ, Inst Nat Med, Toyama 9300194, Japan
[2] Toyama Med & Pharmaceut Univ, Dept Japanese Oriental Med, Toyama 9300194, Japan
[3] Aso Iizuka Hosp, Dept Pathol, Iizuka, Fukuoka 8208505, Japan
关键词
D O I
10.1211/002235702450
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Keishi-bukuryo-gan is a traditional herbal medicine, which is used clinically as a vascular system disorder-eliminating drug. In this study, its effect on the progression of diabetic nephropathy in experimental rats was investigated. The diabetic nephropathy model used in this study shows functional and morphological changes of the kidney resembling those seen in patients with diabetic nephropathy. Increased proteinuria and serum urea nitrogen and creatinine levels and decreased creatinine clearance, which are important parameters of renal function, were observed in rats with diabetic nephropathy. Pathological examination of the kidney revealed diffuse, nodular and exudative lesions and arteriolar hyalinosis. The deterioration of renal function was ameliorated in rats treated with Keishi-bukuryo-gan for 15 weeks and these results agreed with the renal histological findings. In addition, metabolic abnormalities mediated by persistent hyperglycaemia (the glycation reaction, excessive polyol pathway activity, oxidative stress and lipid metabolic abnormalities) were also observed. However, Keishi-bukuryo-gan reduced accumulation of advanced glycation end products, determined by measuring fluorescence, and serum lipid peroxidation, triglyceride and total cholesterol levels dose-dependently. Thus, this study indicates the potential therapeutic usefulness of Keishi-bukuryo-gan for retarding the progression of renal damage and suggests that its beneficial effects were due to its ability to Toyama Medical and improve metabolic abnormalities associated with diabetes.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 28 条
[1]  
ARAI K, 1987, J BIOL CHEM, V262, P16969
[2]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[3]  
Bucala R, 1992, Adv Pharmacol, V23, P1
[4]   THE EFFECT OF ALDOSE REDUCTASE INHIBITORS ON GLOMERULAR PROSTAGLANDIN PRODUCTION AND URINARY ALBUMIN EXCRETION IN EXPERIMENTAL DIABETES-MELLITUS [J].
CHANG, WP ;
DIMITRIADIS, E ;
ALLEN, T ;
DUNLOP, ME ;
COOPER, M ;
LARKINS, RG .
DIABETOLOGIA, 1991, 34 (04) :225-231
[5]   Oxidative stress and diabetic vascular complications [J].
Giugliano, D ;
Ceriello, A ;
Paolisso, G .
DIABETES CARE, 1996, 19 (03) :257-267
[6]  
Goto H., 2000, Journal of Traditional Medicines, V17, P198
[7]   Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C [J].
Ha, H ;
Kim, KH .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 45 (2-3) :147-151
[8]   OXIDATIVE ALTERATIONS IN THE EXPERIMENTAL GLYCATION MODEL OF DIABETES-MELLITUS ARE DUE TO PROTEIN GLUCOSE ADDUCT OXIDATION - SOME FUNDAMENTAL DIFFERENCES IN PROPOSED MECHANISMS OF GLUCOSE-OXIDATION AND OXIDANT PRODUCTION [J].
HUNT, JV ;
BOTTOMS, MA ;
MITCHINSON, MJ .
BIOCHEMICAL JOURNAL, 1993, 291 :529-535
[9]   NON-ENZYMATIC GLUCOSYLATION OF SERUM-PROTEINS IN DIABETES-MELLITUS [J].
MCFARLAND, KF ;
CATALANO, EW ;
DAY, JF ;
THORPE, SR ;
BAYNES, JW .
DIABETES, 1979, 28 (11) :1011-1014
[10]  
MOORHEAD JF, 1991, KIDNEY INT, V39, pS35